Cone-beam computed tomography internal motion tracking should be used to validate 4-dimensional computed tomography for abdominal radiation therapy patients

Leith Rankine, Hanlin Wan, Parag Parikh, Nichole Maughan, Per Poulsen, Todd DeWees, Eric Klein, Lakshmi Santanam

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose To demonstrate that fiducial tracking during pretreatment Cone-Beam CT (CBCT) can accurately measure tumor motion and that this method should be used to validate 4-dimensional CT (4DCT) margins before each treatment fraction. Methods and Materials For 31 patients with abdominal tumors and implanted fiducial markers, tumor motion was measured daily with CBCT and fluoroscopy for 202 treatment fractions. Fiducial tracking and maximum-likelihood algorithms extracted 3-dimensional fiducial trajectories from CBCT projections. The daily internal margin (IM) (ie, range of fiducial motion) was calculated for CBCT and fluoroscopy as the 5th-95th percentiles of displacement in each cardinal direction. The planning IM from simulation 4DCT (IM4DCT) was considered adequate when within ±1.2 mm (anterior-posterior, left-right) and ±3 mm (superior-inferior) of the daily measured IM. We validated CBCT fiducial tracking as an accurate predictive measure of intrafraction motion by comparing the daily measured IMCBCT with the daily IM measured by pretreatment fluoroscopy (IMpre-fluoro); these were compared with pre- and posttreatment fluoroscopy (IMfluoro) to identify those patients who could benefit from imaging during treatment. Results Four-dimensional CT could not accurately predict intrafractional tumor motion for ≥80% of fractions in 94% (IMCBCT), 97% (IMpre-fluoro), and 100% (IMfluoro) of patients. The IMCBCT was significantly closer to IMpre-fluoro than IM4DCT (P<.01). For patients with median treatment time t < 7.5 minutes, IMCBCT was in agreement with IMfluoro for 93% of fractions (superior-inferior), compared with 63% for the t > 7.5 minutes group, demonstrating the need for patient-specific intratreatment imaging. Conclusions Tumor motion determined from 4DCT simulation does not accurately predict the daily motion observed on CBCT or fluoroscopy. Cone-beam CT could replace fluoroscopy for pretreatment verification of simulation IM4DCT, reducing patient setup time and imaging dose. Patients with treatment time t > 7.5 minutes could benefit from the addition of intratreatment imaging.

Original languageEnglish (US)
Pages (from-to)818-826
Number of pages9
JournalInternational Journal of Radiation Oncology Biology Physics
Volume95
Issue number2
DOIs
StatePublished - Jun 1 2016
Externally publishedYes

Fingerprint

fluoroscopy
Cone-Beam Computed Tomography
Fluoroscopy
radiation therapy
cones
Radiotherapy
tomography
Tomography
pretreatment
margins
tumors
Neoplasms
simulation
Fiducial Markers
Therapeutics
Articular Range of Motion
markers
planning
projection
trajectories

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Cone-beam computed tomography internal motion tracking should be used to validate 4-dimensional computed tomography for abdominal radiation therapy patients. / Rankine, Leith; Wan, Hanlin; Parikh, Parag; Maughan, Nichole; Poulsen, Per; DeWees, Todd; Klein, Eric; Santanam, Lakshmi.

In: International Journal of Radiation Oncology Biology Physics, Vol. 95, No. 2, 01.06.2016, p. 818-826.

Research output: Contribution to journalArticle

Rankine, Leith ; Wan, Hanlin ; Parikh, Parag ; Maughan, Nichole ; Poulsen, Per ; DeWees, Todd ; Klein, Eric ; Santanam, Lakshmi. / Cone-beam computed tomography internal motion tracking should be used to validate 4-dimensional computed tomography for abdominal radiation therapy patients. In: International Journal of Radiation Oncology Biology Physics. 2016 ; Vol. 95, No. 2. pp. 818-826.
@article{41705fdc204a4b8ab73f6a7c5c1d046c,
title = "Cone-beam computed tomography internal motion tracking should be used to validate 4-dimensional computed tomography for abdominal radiation therapy patients",
abstract = "Purpose To demonstrate that fiducial tracking during pretreatment Cone-Beam CT (CBCT) can accurately measure tumor motion and that this method should be used to validate 4-dimensional CT (4DCT) margins before each treatment fraction. Methods and Materials For 31 patients with abdominal tumors and implanted fiducial markers, tumor motion was measured daily with CBCT and fluoroscopy for 202 treatment fractions. Fiducial tracking and maximum-likelihood algorithms extracted 3-dimensional fiducial trajectories from CBCT projections. The daily internal margin (IM) (ie, range of fiducial motion) was calculated for CBCT and fluoroscopy as the 5th-95th percentiles of displacement in each cardinal direction. The planning IM from simulation 4DCT (IM4DCT) was considered adequate when within ±1.2 mm (anterior-posterior, left-right) and ±3 mm (superior-inferior) of the daily measured IM. We validated CBCT fiducial tracking as an accurate predictive measure of intrafraction motion by comparing the daily measured IMCBCT with the daily IM measured by pretreatment fluoroscopy (IMpre-fluoro); these were compared with pre- and posttreatment fluoroscopy (IMfluoro) to identify those patients who could benefit from imaging during treatment. Results Four-dimensional CT could not accurately predict intrafractional tumor motion for ≥80{\%} of fractions in 94{\%} (IMCBCT), 97{\%} (IMpre-fluoro), and 100{\%} (IMfluoro) of patients. The IMCBCT was significantly closer to IMpre-fluoro than IM4DCT (P<.01). For patients with median treatment time t < 7.5 minutes, IMCBCT was in agreement with IMfluoro for 93{\%} of fractions (superior-inferior), compared with 63{\%} for the t > 7.5 minutes group, demonstrating the need for patient-specific intratreatment imaging. Conclusions Tumor motion determined from 4DCT simulation does not accurately predict the daily motion observed on CBCT or fluoroscopy. Cone-beam CT could replace fluoroscopy for pretreatment verification of simulation IM4DCT, reducing patient setup time and imaging dose. Patients with treatment time t > 7.5 minutes could benefit from the addition of intratreatment imaging.",
author = "Leith Rankine and Hanlin Wan and Parag Parikh and Nichole Maughan and Per Poulsen and Todd DeWees and Eric Klein and Lakshmi Santanam",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.ijrobp.2016.01.047",
language = "English (US)",
volume = "95",
pages = "818--826",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Cone-beam computed tomography internal motion tracking should be used to validate 4-dimensional computed tomography for abdominal radiation therapy patients

AU - Rankine, Leith

AU - Wan, Hanlin

AU - Parikh, Parag

AU - Maughan, Nichole

AU - Poulsen, Per

AU - DeWees, Todd

AU - Klein, Eric

AU - Santanam, Lakshmi

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Purpose To demonstrate that fiducial tracking during pretreatment Cone-Beam CT (CBCT) can accurately measure tumor motion and that this method should be used to validate 4-dimensional CT (4DCT) margins before each treatment fraction. Methods and Materials For 31 patients with abdominal tumors and implanted fiducial markers, tumor motion was measured daily with CBCT and fluoroscopy for 202 treatment fractions. Fiducial tracking and maximum-likelihood algorithms extracted 3-dimensional fiducial trajectories from CBCT projections. The daily internal margin (IM) (ie, range of fiducial motion) was calculated for CBCT and fluoroscopy as the 5th-95th percentiles of displacement in each cardinal direction. The planning IM from simulation 4DCT (IM4DCT) was considered adequate when within ±1.2 mm (anterior-posterior, left-right) and ±3 mm (superior-inferior) of the daily measured IM. We validated CBCT fiducial tracking as an accurate predictive measure of intrafraction motion by comparing the daily measured IMCBCT with the daily IM measured by pretreatment fluoroscopy (IMpre-fluoro); these were compared with pre- and posttreatment fluoroscopy (IMfluoro) to identify those patients who could benefit from imaging during treatment. Results Four-dimensional CT could not accurately predict intrafractional tumor motion for ≥80% of fractions in 94% (IMCBCT), 97% (IMpre-fluoro), and 100% (IMfluoro) of patients. The IMCBCT was significantly closer to IMpre-fluoro than IM4DCT (P<.01). For patients with median treatment time t < 7.5 minutes, IMCBCT was in agreement with IMfluoro for 93% of fractions (superior-inferior), compared with 63% for the t > 7.5 minutes group, demonstrating the need for patient-specific intratreatment imaging. Conclusions Tumor motion determined from 4DCT simulation does not accurately predict the daily motion observed on CBCT or fluoroscopy. Cone-beam CT could replace fluoroscopy for pretreatment verification of simulation IM4DCT, reducing patient setup time and imaging dose. Patients with treatment time t > 7.5 minutes could benefit from the addition of intratreatment imaging.

AB - Purpose To demonstrate that fiducial tracking during pretreatment Cone-Beam CT (CBCT) can accurately measure tumor motion and that this method should be used to validate 4-dimensional CT (4DCT) margins before each treatment fraction. Methods and Materials For 31 patients with abdominal tumors and implanted fiducial markers, tumor motion was measured daily with CBCT and fluoroscopy for 202 treatment fractions. Fiducial tracking and maximum-likelihood algorithms extracted 3-dimensional fiducial trajectories from CBCT projections. The daily internal margin (IM) (ie, range of fiducial motion) was calculated for CBCT and fluoroscopy as the 5th-95th percentiles of displacement in each cardinal direction. The planning IM from simulation 4DCT (IM4DCT) was considered adequate when within ±1.2 mm (anterior-posterior, left-right) and ±3 mm (superior-inferior) of the daily measured IM. We validated CBCT fiducial tracking as an accurate predictive measure of intrafraction motion by comparing the daily measured IMCBCT with the daily IM measured by pretreatment fluoroscopy (IMpre-fluoro); these were compared with pre- and posttreatment fluoroscopy (IMfluoro) to identify those patients who could benefit from imaging during treatment. Results Four-dimensional CT could not accurately predict intrafractional tumor motion for ≥80% of fractions in 94% (IMCBCT), 97% (IMpre-fluoro), and 100% (IMfluoro) of patients. The IMCBCT was significantly closer to IMpre-fluoro than IM4DCT (P<.01). For patients with median treatment time t < 7.5 minutes, IMCBCT was in agreement with IMfluoro for 93% of fractions (superior-inferior), compared with 63% for the t > 7.5 minutes group, demonstrating the need for patient-specific intratreatment imaging. Conclusions Tumor motion determined from 4DCT simulation does not accurately predict the daily motion observed on CBCT or fluoroscopy. Cone-beam CT could replace fluoroscopy for pretreatment verification of simulation IM4DCT, reducing patient setup time and imaging dose. Patients with treatment time t > 7.5 minutes could benefit from the addition of intratreatment imaging.

UR - http://www.scopus.com/inward/record.url?scp=84961801679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961801679&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2016.01.047

DO - 10.1016/j.ijrobp.2016.01.047

M3 - Article

C2 - 27020102

AN - SCOPUS:84961801679

VL - 95

SP - 818

EP - 826

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -